EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going

Johanna Zandanell, Michael Wießner, Johann W Bauer, Roland N Wagner iD

Experimental Dermatology · 2024

DOI: 10.1111/exd.15042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Johanna Zandanell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria. Hauptthemen laut MEDLINE: Codon, Nonsense, Epidermolysis Bullosa. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helga Kellerhals foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the context of rare genetic diseases caused by nonsense mutations, the concept of induced stop codon readthrough (SCR) represents an attractive avenue in the ongoing search for improved treatment options. Epidermolysis bullosa (EB)—exemplary for this group of diseases—describes a diverse group of rare, blistering genodermatoses. Characterized by extreme skin fragility upon minor mechanical trauma, the most severe forms often result from nonsense mutations that lead to premature translation termination and loss of function of essential proteins at the dermo‐epidermal junction. Since no curative interventions are currently available, medical care is mainly limited to alleviating symptoms and preventing complications. Complementary to attempts of gene, cell and protein therapy in EB, SCR represents a promising medical alternative. While gentamicin has already been examined in several clinical trials involving EB, other potent SCR inducers, such as ataluren, may also show promise in treating the hitherto non‐curative disease. In addition to the extensively studied aminoglycosides and their derivatives, several other substance classes—non‐aminoglycoside antibiotics and non‐aminoglycoside compounds—are currently under investigation. The extensive data gathered in numerous in vitro experiments and the perspectives they reveal in the clinical setting will be discussed in this review.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Codon, NonsenseEpidermolysis BullosaHumansCodon, TerminatorGentamicinsAminoglycosidesAnti-Bacterial Agents

Stichwörter der Autor:innen

aminoglycosidesepidermolysis bullosagentamicinnonsense suppression therapypremature termination codonstop codon readthrough

Substanzen

Codon, TerminatorCodon, NonsenseGentamicinsAminoglycosidesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.

ORCID-Profile: Roland N Wagner

Förderung

  • Helga Kellerhals foundation

Zitieren

APA

Zandanell, J., Wießner, M., Bauer, J. W., & Wagner, R. N. (2024). Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going. Experimental Dermatology. https://doi.org/10.1111/exd.15042

Vancouver

Zandanell J, Wießner M, Bauer JW, Wagner RN. Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going. Experimental Dermatology. 2024. doi:10.1111/exd.15042

BibTeX
@article{Zandanell2024,
  author = {Zandanell, Johanna and Wießner, Michael and Bauer, Johann W and Wagner, Roland N},
  title = {Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.15042}
}
Kostenlos starten →